ZS Podcast · Management Consulting

Optimize Pharmaceutical Market Access Strategies

·32 min·2 clips

The gap between a market signal and pharma action can be 18 months or two years.

The episode opens by contrasting an older era of pharma marketing with the one taking shape now. The earlier model was heavily sales driven and built around pushing the product. The newer one is more customer-centric, although it still looks different from place to place. The pandemic sped that shift up by changing how people in pharma, and in everyday life, use technology. Telemedicine grew quickly, and pharma sales interactions moved from almost entirely face-to-face to a more balanced mix of in-person and remote engagement. That change created new expectations from physicians, who want more virtual engagement across different digital channels. The discussion keeps circling back to one point: this is not only a channel question. It is a customer-experience question. What matters is not whether one channel worked on its own, but how the whole system works together. The episode pushes back on the idea that a rep interaction can just be swapped out for something cheaper and leave everything else untouched. Launch planning comes up as a difficult area in particular. There is real interest in leaner launch models, but the conversation makes clear that this is not simple. Too many other pieces still have to line up, so that future is not here yet. Rather than treating digital as a quick fix, the episode treats it as one part of a larger operating model that still needs careful design. The dialogue also says pharma marketing needs to grow up a bit more. That means more than adopting new tools. It means more attention to training, rethinking processes, and working in a more agile way. There is a repeated call to zoom out from one message or one channel and look at the full customer experience across interactions and channels. The episode suggests the industry is moving, but still has more to learn. It is still working out how to balance human relationships with technology, and how to make those interactions support each other instead of competing. The closing note is practical rather than glossy. Marketers need to listen to customers more carefully. They need to rethink what marketers should be doing. They also need to ask whether their current tools and processes are actually built for the job. The answer, as framed here, is usually no, and that is why the work matters now.

As heard by us

A reset on pharma marketing as hybrid engagement and customer-centric thinking take center stage.

The piece treats pharma marketing as a shift away from an old, sales-first, face-to-face playbook and toward something more customer-led and hybrid.

Read the full review in PlayNext →

Why you'd press play

You want a clear read on how pharma marketing changed after COVID.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from ZS Podcast